{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:21:27Z","timestamp":1767921687723,"version":"3.49.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008436","name":"Ernst and Berta Grimmke Foundation","doi-asserted-by":"publisher","award":["5\/13"],"award-info":[{"award-number":["5\/13"]}],"id":[{"id":"10.13039\/501100008436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.exer.2018.01.003","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T08:02:06Z","timestamp":1515398526000},"page":"49-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Novel everolimus-loaded nanocarriers for topical treatment of murine experimental autoimmune uveoretinitis (EAU)"],"prefix":"10.1016","volume":"168","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2964-8866","authenticated-orcid":false,"given":"Maren","family":"Kasper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Wildsch\u00fctz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herve","family":"Courthion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.R.","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Loser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solon","family":"Thanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gurny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnd","family":"Heiligenhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2018.01.003_bib1","first-page":"395","article-title":"Rodent models of experimental autoimmune uveitis","volume":"102","author":"Agarwal","year":"2004","journal-title":"Meth. Mol. Med."},{"key":"10.1016\/j.exer.2018.01.003_bib2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nm1585","article-title":"T(H)17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1","volume":"13","author":"Amadi-Obi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.exer.2018.01.003_bib3","doi-asserted-by":"crossref","first-page":"500S","DOI":"10.1016\/j.transproceed.2004.01.059","article-title":"Experience with everolimus","volume":"36","author":"Augustine","year":"2004","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.exer.2018.01.003_bib4","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","article-title":"Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells","volume":"105","author":"Battaglia","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exer.2018.01.003_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2337\/diabetes.55.01.06.db05-0613","article-title":"Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance","volume":"55","author":"Battaglia","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.exer.2018.01.003_bib6","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.4049\/jimmunol.177.12.8338","article-title":"Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients","volume":"177","author":"Battaglia","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.exer.2018.01.003_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2165\/00003495-200565040-00005","article-title":"Management of sight-threatening uveitis: new therapeutic options","volume":"65","author":"Becker","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.exer.2018.01.003_bib8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/ard.2006.068320","article-title":"Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritis","volume":"66","author":"Behrens","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.exer.2018.01.003_bib9","first-page":"907","article-title":"Cyclosporin and treatment of non-infectious and recurrent uveitis (apropos of a case of bilateral uveopapillitis)","volume":"88","author":"Boizeau","year":"1988","journal-title":"Bull. Soc. Ophtalmol. Fr."},{"key":"10.1016\/j.exer.2018.01.003_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1167\/iovs.12-10138","article-title":"Effects of systemic and intravitreal TNF-alpha inhibition in experimental autoimmune uveoretinitis","volume":"54","author":"Busch","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.01.003_bib11","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.4049\/jimmunol.140.5.1490","article-title":"A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens","volume":"140","author":"Caspi","year":"1988","journal-title":"J. Immunol."},{"key":"10.1016\/j.exer.2018.01.003_bib12","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.4049\/jimmunol.182.3.1247","article-title":"Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression","volume":"182","author":"Chauhan","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.exer.2018.01.003_bib13","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1167\/iovs.08-1793","article-title":"Diminished frequency and function of CD4+CD25high regulatory T cells associated with active uveitis in Vogt-Koyanagi-Harada syndrome","volume":"49","author":"Chen","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.01.003_bib14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1182\/blood-2005-07-3032","article-title":"Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells","volume":"107","author":"Coenen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exer.2018.01.003_bib15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/sj.bmt.1705628","article-title":"Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells","volume":"39","author":"Coenen","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.exer.2018.01.003_bib16","first-page":"247","article-title":"Cardiac transplantation with the use of cyclosporin a for immunologic suppression","volume":"9","author":"Cooley","year":"1982","journal-title":"Tex. Heart Inst. J.\/from the Texas Heart Institute of St"},{"key":"10.1016\/j.exer.2018.01.003_bib17","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0090-9556(24)15260-9","article-title":"Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats","volume":"27","author":"Crowe","year":"1999","journal-title":"Drug Metabol. Dispos."},{"key":"10.1016\/j.exer.2018.01.003_bib19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/bjo.74.6.344","article-title":"Cyclosporin in the treatment of severe chronic idiopathic uveitis","volume":"74","author":"de Vries","year":"1990","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.01.003_bib20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pharma.2011.01.001","article-title":"Colloidal systems for the delivery of cyclosporin A to the anterior segment of the eye","volume":"69","author":"Di Tommaso","year":"2011","journal-title":"Ann. Pharm. Fr."},{"key":"10.1016\/j.exer.2018.01.003_bib21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijpharm.2011.01.004","article-title":"Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers","volume":"416","author":"Di Tommaso","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.exer.2018.01.003_bib22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2012.02.014","article-title":"Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies","volume":"81","author":"Di Tommaso","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"Suppl. l","key":"10.1016\/j.exer.2018.01.003_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/02713689208999509","article-title":"Experimental autoimmune uveoretinitis: a model system for immunointervention: a review","volume":"11","author":"Forrester","year":"1992","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.exer.2018.01.003_bib24","first-page":"231","volume":"250","author":"Grajewski","year":"2012","journal-title":"Ophthalmologie"},{"key":"10.1016\/j.exer.2018.01.003_bib25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00007890-199501000-00005","article-title":"Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy","volume":"59","author":"Granger","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.exer.2018.01.003_bib26","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.exer.2018.01.003_bib27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.exer.2018.01.003_bib28","first-page":"143","article-title":"Everolimus for the treatment of uveitis refractory to cyclosporine A: a pilot study. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle","volume":"251","author":"Heiligenhaus","year":"2013","journal-title":"Ophthalmologie"},{"key":"10.1016\/j.exer.2018.01.003_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.exer.2012.09.003","article-title":"Everolimus improves experimental autoimmune uveoretinitis","volume":"105","author":"Hennig","year":"2012","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2018.01.003_bib30","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.01.003_bib31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.01.003_bib32","first-page":"253","article-title":"Cyclosporin A: a new advance in transplantation","volume":"9","author":"Kahan","year":"1982","journal-title":"Tex. Heart Inst. J.\/from the Texas Heart Institute of St"},{"key":"10.1016\/j.exer.2018.01.003_bib33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0041-1345(96)00008-5","article-title":"Sirolimus: a new agent for clinical renal transplantation","volume":"29","author":"Kahan","year":"1997","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.exer.2018.01.003_bib34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1365-2125.2000.00293.x","article-title":"Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD","volume":"50","author":"Kirchner","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.exer.2018.01.003_bib35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.112969","article-title":"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine","volume":"69","author":"Kovarik","year":"2001","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"10.1016\/j.exer.2018.01.003_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116800","article-title":"Prevention of herpes simplex virus induced stromal keratitis by a glycoprotein B-specific monoclonal antibody","volume":"10","author":"Krawczyk","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.exer.2018.01.003_bib37","first-page":"1265","volume":"246","author":"Li","year":"2008","journal-title":"Ophthalmologie"},{"key":"10.1016\/j.exer.2018.01.003_bib38","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1084\/jem.20071258","article-title":"Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category","volume":"205","author":"Luger","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.exer.2018.01.003_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000178155","article-title":"Influence of antisense oligonucleotides targeting tumor necrosis factor-alpha on experimental herpetic-induced chorioretinitis of mouse eye","volume":"76","author":"Mei","year":"2009","journal-title":"Pathobiology"},{"key":"10.1016\/j.exer.2018.01.003_bib40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bjo.2006.105528","article-title":"Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis","volume":"91","author":"Murphy","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.01.003_bib41","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1046\/j.1365-2125.1999.00085.x","article-title":"Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients","volume":"48","author":"Neumayer","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.exer.2018.01.003_bib42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1869-5760-3-32","article-title":"Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study","volume":"3","author":"Nguyen","year":"2013","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.exer.2018.01.003_bib43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF00163549","article-title":"The natural history of uveitis","volume":"14","author":"Nussenblatt","year":"1990","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.exer.2018.01.003_bib44","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/archopht.1994.01090230085026","article-title":"Rapamycin inhibits corneal allograft rejection and neovascularization","volume":"112","author":"Olsen","year":"1994","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.exer.2018.01.003_bib45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.exer.2018.01.003_bib46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00007890-199707150-00007","article-title":"SDZ RAD, a new rapamycin derivative: synergism with cyclosporine","volume":"64","author":"Schuurman","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.exer.2018.01.003_bib47","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/S0041-1345(98)00589-2","article-title":"The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation","volume":"30","author":"Schuurman","year":"1998","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.exer.2018.01.003_bib48","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/00007890-200003150-00011","article-title":"Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation","volume":"69","author":"Schuurman","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.exer.2018.01.003_bib49","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.ajo.2011.12.018","article-title":"Subconjunctival sirolimus for the treatment of chronic active anterior uveitis: results of a pilot trial","volume":"153","author":"Sen","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.01.003_bib50","first-page":"1287","article-title":"Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides","volume":"4","author":"Serkova","year":"2003","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.exer.2018.01.003_bib51","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/bjo.2004.048199","article-title":"The efficacy of sirolimus in the treatment of patients with refractory uveitis","volume":"89","author":"Shanmuganathan","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.01.003_bib52","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/bjo.80.9.844","article-title":"The possible impact of uveitis in blindness: a literature survey","volume":"80","author":"Suttorp-Schulten","year":"1996","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.01.003_bib53","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1399-0012.2007.00686.x","article-title":"Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients","volume":"21","author":"Tenderich","year":"2007","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.exer.2018.01.003_bib54","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijpharm.2006.03.036","article-title":"Novel polymeric micelles for hydrophobic drug delivery based on biodegradable poly(hexyl-substituted lactides)","volume":"319","author":"Trimaille","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.exer.2018.01.003_bib55","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/bjo.2008.149039","article-title":"Intermediate uveitis: long-term course and visual outcome","volume":"93","author":"Vidovic-Valentincic","year":"2009","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.01.003_bib56","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.20031579","article-title":"Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis","volume":"199","author":"Viglietta","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.exer.2018.01.003_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.iio.0000155938.83083.94","article-title":"Epidemiology of uveitis","volume":"45","author":"Wakefield","year":"2005","journal-title":"Int. Ophthalmol. Clin."},{"key":"10.1016\/j.exer.2018.01.003_bib58","first-page":"443","volume":"246","author":"Wasmuth","year":"2008","journal-title":"Ophthalmologie"},{"key":"10.1016\/j.exer.2018.01.003_bib59","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0378-4274(91)90171-2","article-title":"The effect of rapamycin on renal function in the rat: a comparative study with cyclosporine","volume":"58","author":"Whiting","year":"1991","journal-title":"Toxicol. Lett."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483517305559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483517305559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T13:21:19Z","timestamp":1751203279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483517305559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":58,"alternative-id":["S0014483517305559"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2018.01.003","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel everolimus-loaded nanocarriers for topical treatment of murine experimental autoimmune uveoretinitis (EAU)","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2018.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}